Brief: Entera Bio Reports Positive PK Data For Oral GLP-2 Tablet For Short Bowel Syndrome At 2025 ESPEN Congress
15/09/2025 14:06
Sept 15 (Reuters) - Entera Bio Ltd 5DT.F: ENTERA BIO REPORTS POSITIVE PK DATA FOR FIRST-IN-CLASS ORAL GLP-2 TABLET TREATMENT FOR PATIENTS WITH SHORT BOWEL SYNDROME AT THE 2025 ESPEN CONGRESS Source text: ID:nGNX915nn0 Further company coverage: 5DT.F ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Entera Bio
See all newsBrief: Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., As Chief Medical Officer Ahead Of Planned Eb613 Phase 3 Initiation
Corrected: Israel's Entera Bio Q2 net loss widens
NASDAQ RESUMED AT 10:02 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:57 AM
Brief: Entera Bio Announces Pricing Of Oversubscribed $275 Million Private Placement